| Effect of Retatrutide Compared With Placebo in Participants With Type 2 Diabetes and Moderate or Severe Renal Impairment, With Inadequate Glycemic Control on Basal Insulin, With or Without Metformin and/or SGLT2 Inhibitor (TRANSCEND-T2D-3) (NCT06297603) | Eli Lilly and Company | 2024-03-15 |
| A Study of Mirikizumab (LY3074828) in Pediatric Participants With Crohn's Disease (NCT05509777) | Eli Lilly and Company | 2024-03-13 |
| A Study of LY4101174 in Participants With Recurrent, Advanced or Metastatic Solid Tumors (NCT06238479) | Eli Lilly and Company | 2024-03-05 |
| A Study to Investigate the Effect of Lepodisiran on the Reduction of Major Adverse Cardiovascular Events in Adults With Elevated Lipoprotein(a) - ACCLAIM-Lp(a) (NCT06292013) | Eli Lilly and Company | 2024-03-05 |
| A Study of LY3537982 in Chinese Participants With Advanced Solid Tumors (NCT06235983) | Eli Lilly and Company | 2024-02-29 |
| Effect of Retatrutide Compared With Semaglutide in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Metformin With or Without SGLT2 Inhibitor (TRANSCEND-T2D-2) (NCT06260722) | Eli Lilly and Company | 2024-02-21 |
| A Study of LY3841136 Compared With Placebo in Adult Participants With Obesity or Overweight (NCT06230523) | Eli Lilly and Company | 2024-02-05 |
| A Study of Orforglipron (LY3502970) Compared With Dapagliflozin in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Metformin (NCT06192108) | Eli Lilly and Company | 2024-01-10 |
| A Study of Carbon-14-Labeled [14C]-LY3549492 in Healthy Participants (NCT06194500) | Eli Lilly and Company | 2024-01-03 |
| A Drug-Drug Interaction Study of Orforglipron (LY3502970) in Healthy Overweight and Obese Participants (NCT06186622) | Eli Lilly and Company | 2024-01-02 |
| A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer (NCT06119581) | Eli Lilly and Company | 2023-12-21 |
| A Multiple Dose Study of LY3209590 in Participants With Type 2 Diabetes (NCT06169982) | Eli Lilly and Company | 2023-12-07 |
| A Study of LY3971297 in Healthy Participants (NCT06148272) | Eli Lilly and Company | 2023-12-07 |
| A Study of LY3972406 in Adult Participants With Moderate-to-Severe Plaque Psoriasis (NCT06176768) | Eli Lilly and Company | 2023-12-06 |
| A First-In-Human Study of LY3839840 in Healthy Participants (NCT06153355) | Eli Lilly and Company | 2023-12-04 |
| A Study of Mirikizumab (LY3074828) in Pediatric Participants With Moderately to Severely or Active Ulcerative Colitis (NCT05784246) | Eli Lilly and Company | 2023-11-22 |
| A Study of LY3305677 Compared With Placebo in Adult Participants With Obesity or Overweight (NCT06124807) | Eli Lilly and Company | 2023-11-17 |
| A Master Protocol Study (LY900038) of Multiple Intervention-Specific-Appendices (ISAs) in Adult Participants With Obesity or Overweight (NCT06143956) | Eli Lilly and Company | 2023-11-17 |
| A Study to Investigate the Safety and Tolerability of LY3938577 in Healthy Participants and Participants With Type 2 Diabetes Mellitus (NCT06132126) | Eli Lilly and Company | 2023-11-17 |
| A Study of Orforglipron (LY3502970) in Participants With Type 2 Diabetes and Inadequate Glycemic Control With Insulin Glargine, With or Without Metformin and/or SGLT-2 Inhibitor (NCT06109311) | Eli Lilly and Company | 2023-11-10 |
| A Study of LY3872386 in Healthy Participants and Participants With Atopic Dermatitis (NCT06119529) | Eli Lilly and Company | 2023-11-01 |
| A Drug-Drug Interaction Study of LY3537982 on Midazolam, Digoxin, and Rosuvastatin in Healthy Participants (NCT06111521) | Eli Lilly and Company | 2023-10-27 |
| A Study of Eltrekibart (LY3041658) in Adult Participants With Moderate to Severe Hidradenitis Suppurativa (NCT06046729) | Eli Lilly and Company | 2023-10-23 |
| A Study of [14C]-LOXO-783 in Healthy Adult Participants (NCT06102512) | Eli Lilly and Company | 2023-10-23 |
| A Phase I Study of LY3502970 in Healthy Participants (NCT06085482) | Eli Lilly and Company | 2023-10-19 |
| A Study of Tirzepatide (LY3298176) Once Weekly in Adolescent Participants Who Have Obesity or Overweight With Weight-Related Comorbidities (NCT06075667) | Eli Lilly and Company | 2023-10-16 |
| A Study of LY3556050 in Adult Participants With Diabetic Peripheral Neuropathic Pain (NCT06074562) | Eli Lilly and Company | 2023-10-05 |
| A Study of LY8888AX in Participants Using a Connected Insulin Management Platform (NCT05893797) | Eli Lilly and Company | 2023-10-05 |
| A Long-term Safety Study of Orforglipron (LY3502970) in Participants With Type 2 Diabetes (NCT06010004) | Eli Lilly and Company | 2023-09-28 |
| A Study of Orforglipron (LY3502970) Compared With Semaglutide in Participants With Type 2 Diabetes Inadequately Controlled With Metformin (NCT06045221) | Eli Lilly and Company | 2023-09-22 |
| A Study of Investigational Tirzepatide (LY3298176) Doses in Participants With Type 2 Diabetes and Obesity (NCT06037252) | Eli Lilly and Company | 2023-09-21 |
| A Study of Carbon-14-Labelled [14C] LY3556050 in Healthy Male Participants (NCT06052462) | Eli Lilly and Company | 2023-09-20 |
| A Study of LY3298176 (Tirzepatide) For the Maintenance of Body Weight Reduction in Participants Who Have Obesity or Overweight With Weight-Related Comorbidities (NCT06047548) | Eli Lilly and Company | 2023-09-20 |
| A Study of LY3437943 in Postmenopausal Female Participants Who Are Overweight or Obese (NCT06039826) | Eli Lilly and Company | 2023-09-12 |
| A Study to Evaluate the Effect of Food on LOXO-783 in Healthy Participants (NCT06028425) | Eli Lilly and Company | 2023-09-01 |
| A Research Study Looking at Similarity Between LY3437943 Versions for Different Injection Devices (NCT06003465) | Eli Lilly and Company | 2023-08-29 |
| A Single and Multiple Ascending Dose Study of LY3876602 in Healthy Participants (NCT06007638) | Eli Lilly and Company | 2023-08-23 |
| A Study of Tirzepatide (LY3298176) in Chinese Participants With Type 2 Diabetes (SURPASS-CN-MONO) (NCT05963022) | Eli Lilly and Company | 2023-08-21 |
| A Study of LY3885125 in Participants With Dyslipidemia or Non-Alcoholic Fatty Liver Disease (NAFLD) (NCT06007651) | Eli Lilly and Company | 2023-08-10 |
| A Study of LY3871801 in Healthy Asian and Non-Asian Participants (NCT05960851) | Eli Lilly and Company | 2023-08-09 |
| A Study of Orforglipron (LY3502970) in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Diet and Exercise Alone (NCT05971940) | Eli Lilly and Company | 2023-08-09 |
| A Study of Retatrutide (LY3437943) Once Weekly in Participants Who Have Obesity or Overweight and Osteoarthritis of the Knee (NCT05931367) | Eli Lilly and Company | 2023-08-01 |
| A Study of Tirzepatide (LY3298176) in Healthy Lactating Females (NCT05978713) | Eli Lilly and Company | 2023-07-31 |
| A Study of Once-Daily Oral Orforglipron (LY3502970) in Japanese Adult Participants With Obesity Disease (NCT05931380) | Eli Lilly and Company | 2023-07-31 |
| A Drug Drug Interaction (DDI) Study of Selpercatinib (LY3527723) and Rosuvastatin in Healthy Participants (NCT05906836) | Eli Lilly and Company | 2023-07-27 |
| A Relative Bioavailability Study of Peresolimab (LY3462817) Formulations in Healthy Participants (NCT05959109) | Eli Lilly and Company | 2023-07-21 |
| A Study of Retatrutide (LY3437943) on Renal Function in Participants With Overweight or Obesity and Chronic Kidney Disease With or Without Type 2 Diabetes (NCT05936151) | Eli Lilly and Company | 2023-07-20 |
| A Study of LY3437943 in Healthy Participants With a High Body Mass Index (NCT05959096) | Eli Lilly and Company | 2023-07-18 |
| A Study of LY3437943 in Participants With Impaired and Normal Liver Function (NCT05916560) | Eli Lilly and Company | 2023-07-13 |
| A Study of Retatrutide (LY3437943) in Participants With Type 2 Diabetes Mellitus Who Have Obesity or Overweight (NCT05929079) | Eli Lilly and Company | 2023-07-11 |
| A Study of Retatrutide (LY3437943) in Participants Who Have Obesity or Overweight (NCT05929066) | Eli Lilly and Company | 2023-07-10 |
| A Study to Compare Two Formulations of LY3819469 in Healthy Participants (NCT05932446) | Eli Lilly and Company | 2023-06-30 |
| A Study of Ixekizumab (LY2439821) in Participants Aged ≥18 Years With Moderate-to-Severe Plaque or Active Psoriatic Arthritis in India (NCT05855967) | Eli Lilly and Company | 2023-06-27 |
| A Study to Compare Two Formulations of LY3209590 in Healthy Participants (NCT05914688) | Eli Lilly and Company | 2023-06-26 |
| A Study of LY3502970 in Participants With Impaired and Normal Liver Function (NCT05882032) | Eli Lilly and Company | 2023-06-13 |
| A Study of LY3532226 in Participants With Type 1 Diabetes Mellitus (NCT05887999) | Eli Lilly and Company | 2023-06-12 |
| A Study to Evaluate the Effect of Cholestyramine on LOXO-783 in Healthy Participants (NCT05894928) | Eli Lilly and Company | 2023-06-07 |
| A Study of Orforglipron in Adult Participants With Obesity or Overweight and Type 2 Diabetes (NCT05872620) | Eli Lilly and Company | 2023-06-05 |
| A Study of [14C]-LY3537982 in Healthy Participants (NCT05901311) | Eli Lilly and Company | 2023-06-05 |
| A Study of Orforglipron (LY3502970) in Adult Participants With Obesity or Overweight With Weight-Related Comorbidities (NCT05869903) | Eli Lilly and Company | 2023-06-05 |
| A Study of Retatrutide (LY3437943) in Participants With Obesity and Cardiovascular Disease (NCT05882045) | Eli Lilly and Company | 2023-05-30 |
| An Adaptive Phase 2a/2b Study of LY3871801 in Adult Participants With Rheumatoid Arthritis (NCT05848258) | Eli Lilly and Company | 2023-05-23 |
| A Study of Mirikizumab (LY3074828) in Participants With Moderately to Severely Active Ulcerative Colitis (NCT05767021) | Eli Lilly and Company | 2023-05-17 |
| A Study of the Effects of Itraconazole or Carbamazepine on LY3537982 in Healthy Participants (NCT05860933) | Eli Lilly and Company | 2023-05-08 |
| A Multiple Dose Study of LY3502970 in Healthy Overweight and Obese Participants (NCT05841238) | Eli Lilly and Company | 2023-04-26 |
| A Study of LY3819469 in Participants With Impaired and Normal Renal Function (NCT05841277) | Eli Lilly and Company | 2023-04-25 |
| First-in-Human Study of Tersolisib (STX-478) as Monotherapy and in Combination With Other Antineoplastic Agents in Participants With Advanced Solid Tumors (NCT05768139) | Eli Lilly and Company | 2023-04-17 |
| A Study of the Effect of Food on LY3537982 in Healthy Participants (NCT05824858) | Eli Lilly and Company | 2023-04-12 |
| A Research Study Looking at Similarity Between Tirzepatide Versions for Different Injection Devices (NCT05810597) | Eli Lilly and Company | 2023-04-03 |
| A Study of Daily Oral Orforglipron (LY3502970) Compared With Insulin Glargine in Participants With Type 2 Diabetes and Obesity or Overweight at Increased Cardiovascular Risk (NCT05803421) | Eli Lilly and Company | 2023-04-03 |
| A Multiple-Dose Study of LY3493269 in Healthy Participants (NCT05794243) | Eli Lilly and Company | 2023-03-23 |
| A Study of LY3473329 in Participants With Impaired and Normal Renal Function (NCT05778864) | Eli Lilly and Company | 2023-03-17 |
| A Study of Carbon-14-Labelled [14C] LY3437943 in Healthy Male Participants (NCT05757531) | Eli Lilly and Company | 2023-03-17 |
| A Study to Assess the Long-Term Safety and Efficacy of Lebrikizumab (LY3650150) in Participants 6 Months to <18 Years of Age With Moderate-to-Severe Atopic Dermatitis (NCT05735483) | Eli Lilly and Company | 2023-03-09 |
| A Study of Tirzepatide (LY3298176) in Adults With Type 2 Diabetes Switching From a GLP-1 RA (SURPASS-SWITCH-2) (NCT05706506) | Eli Lilly and Company | 2023-03-08 |
| A Study of Different Donanemab (LY3002813) Dosing Regimens in Adults With Early Alzheimer's Disease (TRAILBLAZER-ALZ 6) (NCT05738486) | Eli Lilly and Company | 2023-02-28 |
| A Study of Baricitinib (LY3009104) in Children From 6 Years to Less Than 18 Years of Age With Alopecia Areata (NCT05723198) | Eli Lilly and Company | 2023-02-27 |
| A Study of Carbon-14-Labelled [14C] LY3372689 in Healthy Male Participants (NCT05749848) | Eli Lilly and Company | 2023-02-24 |
| A Phase I Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of DC-853 in Healthy Participants (NCT06937411) | Eli Lilly and Company | 2023-02-13 |
| A Study of LY3848575 in Healthy Participants (NCT05727072) | Eli Lilly and Company | 2023-02-10 |
| A Study of Tirzepatide (LY3298176) in Participants With Overweight or Obesity and Chronic Kidney Disease With or Without Type 2 Diabetes (NCT05536804) | Eli Lilly and Company | 2023-02-08 |
| A Study of Tirzepatide (LY3298176) in Pediatric Participants With Obesity (NCT05696847) | Eli Lilly and Company | 2023-02-07 |
| A Study of Tirzepatide (LY3298176) in Chinese Participants With Type 2 Diabetes (NCT05691712) | Eli Lilly and Company | 2023-02-05 |
| A Study of LY3540378 in Participants With Worsening Chronic Heart Failure With Preserved Ejection Fraction (HFpEF) (NCT05592275) | Eli Lilly and Company | 2023-02-03 |
| A Study of Continuous Blood Pressure Monitoring in Healthy Participants (NCT05692869) | Eli Lilly and Company | 2023-01-31 |
| A Study of Insulin Efsitora Alfa (LY3209590) Compared to Glargine in Adult Participants With Type 2 Diabetes Who Are Starting Basal Insulin for the First Time (QWINT-1) (NCT05662332) | Eli Lilly and Company | 2023-01-14 |
| A Study of (LY3650150) Lebrikizumab to Assess the Safety and Efficacy of Adult and Adolescent Participants With Moderate-to-Severe Atopic Dermatitis and Skin of Color (NCT05372419) | Eli Lilly and Company | 2023-01-12 |
| FORAGER-1: A Study of LOXO-435 (LY3866288) in Participants With Cancer With a Change in a Gene Called FGFR3 (NCT05614739) | Eli Lilly and Company | 2023-01-12 |
| A Study of Dulaglutide (LY2189265) in Participants With Type 2 Diabetes Mellitus in India (NCT05659537) | Eli Lilly and Company | 2022-12-29 |
| A Study of Lebrikizumab (LY3650150) in Adult and Adolescent Participants With Moderate-to-Severe Atopic Dermatitis Previously Treated With Dupilumab (NCT05369403) | Eli Lilly and Company | 2022-12-19 |
| A Chronic Pain Master Protocol (CPMP): A Study of LY3857210 in Participants With Chronic Low Back Pain (NCT05630196) | Eli Lilly and Company | 2022-12-08 |
| A Bioequivalence Study of Mirikizumab (LY3074828) Solution in Healthy Participants (NCT05644353) | Eli Lilly and Company | 2022-12-05 |
| A Study of LY3209590 in Chinese Participants With Type 2 Diabetes Mellitus (NCT05596747) | Eli Lilly and Company | 2022-11-30 |
| A Study of Tirzepatide (LY3298176) in Adult Participants With Type 2 Diabetes Switching From Dulaglutide (SURPASS-SWITCH) (NCT05564039) | Eli Lilly and Company | 2022-11-30 |
| A Study of LY3473329 in Adult Participants With Elevated Lipoprotein(a) at High Risk for Cardiovascular Events (NCT05563246) | Eli Lilly and Company | 2022-11-24 |
| A Chronic Pain Master Protocol (CPMP): A Study of LY3857210 In Participants With Osteoarthritis Pain (NCT05620563) | Eli Lilly and Company | 2022-11-22 |
| A Study of LY3437943 in Healthy Participants and Participants With Impaired Renal Function (NCT05611957) | Eli Lilly and Company | 2022-11-16 |
| Safety and Efficacy of Bimagrumab and Semaglutide in Adults Who Are Overweight or Obese (NCT05616013) | Eli Lilly and Company | 2022-11-16 |
| A Study of LY3305677 in Participants With Obesity Or Overweight (NCT05623839) | Eli Lilly and Company | 2022-11-16 |
| A Study of Effect of LY3556050 on Metformin in Healthy Participants (NCT05615467) | Eli Lilly and Company | 2022-11-15 |